T1	p 77 106	anemic patients with cancer .
T2	p 222 271	patients with cancer-associated anemia . PATIENTS
T3	p 284 306	Eligible patients were
T4	p 577 685	hundred sixty-five patients were enrolled . One hundred eighty-three patients were assigned to the 40K arm ,
T5	i 59 73	erythropoietin
T6	i 138 150	epoetin alfa
T7	i 205 217	epoetin alfa
T8	i 372 415	epoetin alfa 40,000 U subcutaneously ( SC )
T9	i 437 471	standard weekly epoetin alfa ( 40K
T10	i 494 513	epoetin alfa ( 120K
T11	i 518 522	) SC
T12	i 1544 1563	epoetin alfa 40,000
T13	i 1586 1587	U
T14	i 1751 1763	epoetin alfa
T15	o 757 802	proportion of patients requiring transfusions
T16	o 1075 1077	Hb
T17	o 1170 1261	mean end-of-study Hb levels . Toxicities , including thromboembolism , and overall survival
T18	o 1307 1344	higher global quality of life ( QOL )
T19	o 1426 1448	global QOL improvement
T20	o 1484 1487	QOL
T21	o 1686 1689	QOL
T22	o 1696 1698	Hb